Attend the FierceBiotech Executive Breakfast at BIO 2019
Join us on June 5th for our panel discussion on real-world evidence. Reserve your seat today.
The FDA says Torrent finished product batches were out of spec 340 times in two years, but the company often approved them after retesting.
Takeda sells meds to Novartis and J&J; Daiichi's AZ-shared HER2 antibody-drug conjugate hits key trial goal; Sun scouts for Chinese partner.
Novartis hopes the deal, potentially worth $5.3 billion, could better position itself in front-of-the-eye therapies.
AZ warns of slower China growth; BeiGene chief ranks among highest-paid biopharma CEOs; Kangmei faces delisting over huge accounting "error."
Keytruda grew sales by 60% at constant currencies, boosting its share in Merck's portfolio. Could China and a few new indications step on the gas?
BeiGene CEO John Oyler's $27.9 million pay in 2018 surpassed many Big Pharma and Big Biotech pay packages, but it's likely a one-time thing.
Lilly sells legacy antibiotics in China; Daiichi picks a bispecific antibody in Zymeworks deal; Torrent recalls more than 1 million losartan bottles.
China sales and older meds helped boost Bayer's pharma results, but those numbers couldn't eclipse concerns about mushrooming Monsanto litigation.
Sun Pharma has been issued a Form 483, Catalent is investing $14 million at a facility in Germany and more manufacturing news of note.
Amid China's tighter grip on antibiotics use, Lilly sold Chinese rights to two legacy antibiotics and a manufacturing facility to China's Eddingpharm.